Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
The rally attracted around 250 riders, including professionals and amateurs.
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
New Regional Processing Lab will serve Ahmedabad and the state of Gujarat
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
India is at a key inflexion point of not just ‘Heal in India’ through its vibrant medical value tourism, but also ‘Heal by India’, where our medical professionals can be used to serve not just our country but at the global level.
AstraZeneca also played a critical role in the global response to COVID-19.
Subscribe To Our Newsletter & Stay Updated
